Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Masanori Oshi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1404-1570; OpenAlex author ID A5029088912. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  2. High CDCP1 Expression Reflects Immune and Stromal Remodeling and Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma. First author DOI 10.14740/wjon2682↗
  3. Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclit… Co-author DOI 10.1016/j.esmogo.2025.100221↗
  4. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  5. SLC7A11 and the glutathione pathway as novel prognostic markers in resectable pancreatic ductal adenocarcinoma: A metabolomics study of clinical specimens. Co-author DOI 10.1016/j.pan.2024.05.530↗
  6. A Case of BRCA2-Pathogenic Variant Breast Cancer With Metachronous Endometrial Cancer and Pancreatic Cancer. Co-author DOI 10.14740/wjon1658↗
  7. Pancreatic ductal adenocarcinoma with a high expression of alcohol dehydrogenase 1B is associated with less aggressive features and a favorable prognosis. First author PMID 37693153↗
  8. High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis. First author PMID 37818071↗
  9. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Co-author DOI 10.3390/cells10030653↗
  10. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Co-author PMID 34249445↗
  11. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Co-author DOI 10.3390/cancers12102871↗
  12. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers12123635↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 11 shared papers, 2020–2026 · strength 2.15
  2. Kazuaki Takabe · 6 shared papers, 2020–2023 · strength 1.01
  3. Li Yan · 4 shared papers, 2020–2021 · strength 0.53
  4. Kentaro Miyake · 2 shared papers, 2024–2026 · strength 0.52
  5. Yoshiaki Murakami · 2 shared papers, 2025–2026 · strength 0.44
  6. Sohei Satoi · 2 shared papers, 2025–2026 · strength 0.44
  7. Shuji Isaji · 2 shared papers, 2025–2026 · strength 0.44
  8. Suguru Yamada · 2 shared papers, 2025–2026 · strength 0.44
  9. Masayuki Sho · 2 shared papers, 2025–2026 · strength 0.44
  10. Hiroki Yamaue · 2 shared papers, 2025–2026 · strength 0.44
  11. Takashi Murakami · 2 shared papers, 2025–2026 · strength 0.44
  12. Yasuhiro Yabushita · 2 shared papers, 2025–2026 · strength 0.44
  13. Michiaki Unno · 2 shared papers, 2025–2026 · strength 0.44
  14. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.44
  15. Goro Honda · 2 shared papers, 2025–2026 · strength 0.44
  16. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.44
  17. Yuki Homma · 1 shared paper, 2026 · strength 0.29
  18. Jun Yamamoto · 1 shared paper, 2026 · strength 0.29
  19. Brendan L. Hagerty · 1 shared paper, 2023 · strength 0.26
  20. Matthew H. G. Katz · 2 shared papers, 2020 · strength 0.24
  21. Hiroki Ohya · 1 shared paper, 2024 · strength 0.23
  22. Kohei Chida · 1 shared paper, 2023 · strength 0.22
  23. Makoto Sugimori · 1 shared paper, 2025 · strength 0.21
  24. Manabu Morimoto · 1 shared paper, 2025 · strength 0.21
  25. Hajime Yamazaki · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.